Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

NCT06627413 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia or Schizoaffective

Interventions

DRUG: Lumateperone Capsule
DRUG: Lumateperone LAI
DRUG: Lumateperone LAI
DRUG: Lumateperone LAI
DRUG: Lumateperone LAI
DRUG: Lumateperone LAI

Sponsor

Intra-Cellular Therapies, Inc.